Global Multi Cancer Early Detection Market Size, Share, Growth & Trends Report Segmented by Type (Liquid Biopsy, Gene Panel, LDT), End-user (Hospitals, Diagnostic Centers, Others) Industry Analysis & Regional Forecast to 2030
The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period. This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth. To learn more about the research report, download a sample report.
Report Overview
Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive.
To learn more about this report, download the PDF brochure
Global cancer burden and the rising shift toward multi cancer early detection
The primary factor driving this market is the simple fact that cancer is still one of the leading causes of mortality around the world. According to an article published by the WHO, there were around 20 million new cases of cancer and 9.7 million deaths from cancer in the year 2022. The burden is expected to increase by 77% by 2050, and will further put more pressure on healthcare systems. The rising awareness about early detection of cancer and the surge in the number of cancer cases globally have spurred a major shift in screening methods. Instead of waiting for symptoms or relying on invasive, one cancer at a time tests, many healthcare providers are now leaning toward quicker, more inclusive methods like MCED, which requires a single blood draw and can check for multiple cancers, making it not just convenient but also more likely to get people screened in the first place. As clinical evidence continues to build and regulatory pathways evolve, these tests are poised to see much wider adoption in the years ahead.
DNA methylation profiling: a breakthrough enhancing test accuracy and adoption
cfDNA methylation profiling is one of the notable innovations making MCED more accurate and practical. Traditional screening methods include hunting for specific mutations; this test looks at how DNA is tagged with chemical markers called methylation which changes depending on the type and location of cancer. Even if there’s only a tiny amount of tumor DNA in the blood, these unique patterns can still be detected and used to trace the cancer’s origin. The test gives better precision, compared to other methods, meaning fewer false alarms and less need for stressful follow-up tests. The preliminary data for this test seems to be promising, due to which physicians are incorporating it in everyday preventive care, not just for early diagnosis, but for the entire conversation around cancer care. For instance, in February 2025, GRAIL partnered with Quest Diagnostics to make its Galleri test directly accessible to over 500,000 healthcare providers and 7,400 collection sites across the US through Quest Diagnostics' ordering system
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global multi cancer early detection market is marked by the presence of established and emerging market players such Illumina, Inc.; GRAIL, Inc.; Exact Sciences Corporation; FOUNDATION MEDICINE, INC.; Guardant Health; Freenome Holdings, Inc; Elypta AB; AnchorDx and Burning Rock Biotech Limited among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 – 2030 |
| Growth Rate | 15-20% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Type and End-user |
| Regional Scope |
|
| Key Companies Mapped | Illumina, Inc.; GRAIL, Inc.; Exact Sciences Corporation; FOUNDATION MEDICINE, INC.; Guardant Health; Freenome Holdings, Inc; Elypta AB; AnchorDx and Burning Rock Biotech Limited among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Multi Cancer Early Detection Market Segmentation
This report by Medi-Tech Insights provides the size of the global multi cancer early detection market at the regional- and country-level from 2023 to 2030. The report further segments the market based on type and end-user.
Market Size & Forecast (2023-2030), By Type, USD Million
- Liquid Biopsy
- Gene Panel
- LDT & Others
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Centers
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the multi cancer early detection market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the multi cancer early detection market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Multi Cancer Early Detection Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Rising global cancer incidence
- Growing demand for minimally invasive screening
- Advancements in liquid biopsy technologies
- Increasing awareness of preventive healthcare
- Rising public and private investments in cancer diagnostics
- Restraints
- High test costs limiting widespread access
- Regulatory hurdles and lack of standardized approval pathways
- Limited reimbursement coverage in many regions
- Opportunities
- Potential for integration into national cancer screening programs
- Expansion into emerging markets
- Development of decentralized and at-home testing models
- Strategic collaborations between tech and healthcare providers
- Key Market Trends
- Growing use of epigenetic biomarkers
- Rising investment in multi-omics approaches
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Multi Cancer Early Detection Market Size & Forecast (2023-2030), By Type, USD Million
- Introduction
- Liquid Biopsy
- Gene Panel
- LDT & Others
- Global Multi Cancer Early Detection Market Size & Forecast (2023-2030), By End-user, USD Million
- Introduction
- Hospitals
- Diagnostic Centers
- Others
- Global Multi Cancer Early Detection Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Multi Cancer Early Detection Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Canada
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- US
- Europe Multi Cancer Early Detection Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Germany
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- France
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Italy
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Spain
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Europe
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- UK
- Asia Pacific (APAC) Multi Cancer Early Detection Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Japan
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- India
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- China
- Latin America (LATAM) Multi Cancer Early Detection Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Middle East & Africa (MEA) Multi Cancer Early Detection Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Illumina, Inc.
- GRAIL, Inc.
- Exact Sciences Corporation
- FOUNDATION MEDICINE, INC
- Guardant Health
- Freenome Holdings, Inc
- Elypta AB
- AnchorDx
- Burning Rock Biotech Limited
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Diagnostic Centers and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
